Generative AI Use Cases: A Pharma Program From Pilot to Scale

Generative AI Use Cases become meaningful in biopharma when they are evaluated against the actual friction of moving a molecule from candidate nomination toward clinical proof and reliable supply. This case study follows a fictional but operationally realistic research-based company, Meridian BioPharma, as it deploys generative AI across one oncology program. The details are constructed from common industry patterns: fragmented evidence, repeated regulatory authoring, protocol complexity, pharmacovigilance workload, and manufacturing investigations that compete for scarce scientific attention.

The program illustrates how Generative AI Use Cases can be connected without pretending that one model can run discovery, clinical development, safety, and CMC. Meridian created several bounded assistants over a common evidence architecture, assigned accountable reviewers, and measured outcomes over eighteen months. Its experience offers a useful counterpoint to demonstrations that report impressive text-generation speed but never show whether cycle time, evidence quality, or decision confidence improved.

The Starting Point: A Promising Asset and a Fragmented Evidence Trail

Meridian had nominated MBP-417, an oral small-molecule inhibitor for a genetically defined solid-tumor population. The program had progressed through target validation, target-to-hit work, hit-to-lead progression, and eighteen months of lead optimization. Candidate nomination relied on biochemical and cellular potency, selectivity panels, microsomal stability, permeability, off-target profiling, and early in vivo pharmacokinetics/pharmacodynamics. Although the evidence supported advancement, it was scattered across an electronic laboratory notebook, assay repositories, compound-registration records, study reports, slide decks, and email decisions.

The asset team faced four near-term deliverables. It needed to complete IND-enabling studies, author the IND, design a first-in-human protocol, and transfer the drug-substance process from a development laboratory to a pilot GMP facility. At baseline, scientists spent an estimated 26 percent of document-preparation time locating and reconciling evidence. Regulatory authors maintained manual source tables. Clinical scientists reviewed historical protocols one document at a time. Process-development staff searched deviation archives using keywords that missed semantically related events.

Leadership set three constraints. No model output could serve as an approved GxP record without qualified human review. Patient-level clinical or safety data would remain inside the controlled environment. Every material scientific claim had to retain source provenance. Rather than promising autonomous development, the team defined success as faster evidence assembly, fewer avoidable inconsistencies, and earlier identification of risks.

Phase One: Building an Evidence Layer for IND Preparation

The first implementation addressed regulatory authoring because the program had a fixed submission date and a measurable baseline. A cross-functional team indexed approved pharmacology, pharmacokinetics, ADME/Tox, bioanalytical, and CMC documents. Each source was tagged by study, species, compound form, data cutoff, approval state, and document version. Tables were captured with units and footnotes rather than converted into unstructured text. Superseded reports remained accessible but were excluded from default retrieval.

The authoring assistant did not generate an entire IND module from a short instruction. It assembled evidence packages for narrowly defined sections, proposed structured outlines, drafted source-grounded summaries, and flagged conflicting values. Every paragraph displayed its supporting sources and marked statements that involved interpretation. Authors could accept, revise, or reject the draft, but could not remove provenance from the review record.

During a twelve-week pilot, the team compared eight assisted sections with six similar sections prepared through the established process. Median first-draft time fell from 11.5 working days to 7.2 days, a 37 percent reduction. Time spent locating source evidence decreased by 52 percent. Quality-control reviewers identified 31 percent fewer cross-section inconsistencies, largely because compound identifiers, study numbers, and dose units were inserted from controlled metadata.

The result was not uniformly positive. Reviewers initially spent 18 percent more time checking narrative transitions because early prompts encouraged the model to smooth over differences between GLP reports. After the workflow was changed to prohibit reconciliation without an explicit author decision, review time returned below baseline. This became the first major lesson: Generative AI Use Cases must surface scientific disagreement, not conceal it behind fluent prose.

Phase Two: AI Drug Discovery Support for Translational Questions

Although MBP-417 had already reached candidate nomination, the discovery organization used the same evidence layer to examine translational hypotheses. The team connected curated assay results, compound structures, target biology, resistant-cell-line findings, and public-domain mechanistic literature. An AI Drug Discovery assistant generated testable questions about pathway escape, potential combination strategies, and biomarkers that might distinguish pharmacodynamic response from general cytotoxicity.

Scientists evaluated 64 generated hypotheses using a rubric for biological plausibility, novelty, available evidence, experimental feasibility, and program relevance. Eleven were considered useful enough for discussion, five entered experimental planning, and two produced actionable findings. One suggested stratifying a resistant-cell-line panel by a compensatory signaling marker that had been measured but not integrated with response data. The analysis did not establish causality, but it directed a follow-up experiment that influenced an exploratory biomarker plan.

The metrics prevented exaggerated claims. The model did not discover the target or nominate MBP-417. Most suggestions were redundant, insufficiently specific, or unsupported by the available evidence. Its value came from traversing disconnected observations faster than a project team could manually. The productive unit was not the number of ideas generated; it was the small fraction of traceable hypotheses that survived expert challenge and led to an informative experiment.

Phase Three: Protocol Design and Feasibility

Meridian next introduced Clinical Development AI during first-in-human protocol design. The assistant retrieved prior oncology protocols, dose-escalation conventions, nonclinical safety findings, anticipated human exposure, biomarker requirements, and site-feasibility evidence. It generated comparisons rather than a finished protocol, showing how alternative eligibility criteria, visit schedules, and sampling plans affected patient burden and data interpretability.

A central debate concerned intensive pharmacokinetic sampling. The original schedule required two long clinic days in the first cycle and created processing demands that several candidate sites could not reliably meet. The assistant compared schedules from internal studies, linked sampling windows to the pharmacometric objectives, and summarized feasibility feedback. Pharmacometricians then designed a reduced schedule that preserved the information needed for initial exposure modeling while lowering site burden.

The final protocol contained 14 percent fewer distinct assessment time points than the preliminary concept. The number of site questions during feasibility review fell from a historical median of 46 to 32. Protocol-authoring time decreased by 23 percent, and all medical, statistical, operational, and patient-facing decisions remained under conventional governance. Six months after first-patient-in, recruitment was 12 percent above the scenario-adjusted internal forecast. Meridian did not attribute that result solely to the assistant; country activation, investigator engagement, and the biomarker-defined population also mattered.

This phase demonstrated why Generative AI Use Cases need outcome chains rather than isolated productivity measures. Faster drafting was useful, but the more valuable result was a protocol with fewer operationally questionable requirements. Clinical development benefited because the system helped experts compare consequences before commitments reached sites and patients.

Phase Four: Safety Intake and Medical Review

Once dosing began, the pharmacovigilance organization piloted an assistant for literature surveillance and case-processing support. Pharmacovigilance AI screened retrieved articles for potential individual case safety reports, extracted patient and product details, suggested MedDRA concepts, and prepared a narrative draft. It did not determine final seriousness, expectedness, causality, or reportability, and it could not submit a case.

The validation set contained 2,400 historical abstracts and full-text articles, deliberately enriched with difficult cases involving class effects, multiple products, secondary citations, pregnancy exposure, and unclear patient counts. At the selected operating threshold, the system achieved 97.8 percent recall for articles containing potential valid cases and 88.6 percent precision. The remaining false positives were routed to trained surveillance staff. Meridian accepted the lower precision because the risk of missing a reportable case outweighed the cost of additional review.

Across the first four months, median screening time per article decreased by 41 percent. For confirmed cases, prepopulation and narrative drafting reduced initial processing effort by 28 percent. Quality sampling found no increase in significant data-entry errors, but reviewers frequently corrected temporal relationships and medical-history distinctions. Those corrections became monitored categories rather than training data that flowed automatically into the production system.

The company also tested automated AI text detectors on generated safety narratives. The experiment showed that origin classification did not answer the questions safety reviewers actually faced: whether the chronology was accurate, whether medically relevant details were omitted, and whether every statement was supported by case evidence. Meridian retained provenance and field-level comparison as controls and abandoned detection scores as a release criterion.

Phase Five: Technology Transfer and Deviation Investigation

During technology transfer, the drug-substance process showed greater filtration variability at pilot scale than in the development laboratory. Two engineering batches remained within specification but required extended processing, creating concern about GMP scheduling and future commercial scale-up. The manufacturing assistant retrieved development reports, equipment characteristics, raw-material data, batch observations, and historical deviations from chemically related processes.

It produced a structured hypothesis map covering particle-size distribution, solvent composition, temperature trajectory, filter loading, and hold time. Each hypothesis linked to supporting and contradicting evidence. Process engineers combined those suggestions with first-principles analysis and identified an interaction between crystallization endpoint variability and the effective filter area. A focused study supported revised in-process controls and an updated scale-dependent operating range.

The next three batches completed filtration within the planned window. Investigation drafting time fell from a historical median of 19 days to 13 days, while quality assurance requested fewer evidence-related revisions. The assistant also proposed CAPA language, but QA required investigators to write the final effectiveness criteria because early drafts were too generic. Lot disposition remained entirely with the established quality unit.

This was one of the most valuable Generative AI Use Cases because it reused development knowledge at the moment a scale-up problem emerged. It also showed the limits of similarity retrieval. A prior deviation is useful only when product, equipment, process version, material attributes, and control strategy are visible. Without context, precedent can mislead an investigation as easily as it can accelerate one.

The Governance Model Behind the Metrics

Meridian organized the program around intended use rather than a universal chatbot. Each assistant had a process owner, scientific or medical owner, technical owner, and risk classification. The regulatory assistant was governed as an authoring aid; the safety workflow received more stringent validation because errors could affect expedited reporting; the manufacturing application operated within deviation and change-control procedures.

Challenge sets were built from authentic work examples and refreshed when failure patterns emerged. Evaluation covered factual support, source fidelity, omissions, unit preservation, abstention, and reviewer-detection rates. Model or retrieval changes required impact assessment. Access was role-based, prompts and outputs were logged according to approved retention rules, and users received training on intended use and escalation.

These controls initially added approximately seven weeks to the first deployment. They shortened later implementations because teams reused the evidence connectors, evaluation framework, access model, and review components. By month eighteen, the shared platform supported seven workflows. Pharmaceutical AI Solutions became a portfolio capability only after common controls reduced the cost of introducing each additional application.

What the Business Case Actually Showed

Meridian estimated 18,700 hours of gross annualized capacity across regulatory writing, evidence search, protocol development, literature screening, case preparation, and deviation investigation. After subtracting review, monitoring, platform support, and periodic validation effort, net capacity was approximately 11,900 hours. The company did not convert that figure directly into head-count reduction. It redirected capacity toward submission strategy, medical review, site support, signal evaluation, and process characterization.

More important than capacity were three decision-quality indicators. Source-related regulatory findings decreased, protocol feasibility questions became easier to resolve before approval, and manufacturing investigations reached testable hypotheses sooner. No application was allowed to claim reduced attrition because the observation period was too short and a single oncology program could not support that conclusion.

The finance review found that integration, curation, and validation represented 63 percent of first-year cost; model consumption represented only 9 percent. That distribution changed the investment conversation. Generative AI Use Cases were not primarily a model-procurement exercise. They were an evidence-engineering and workflow-redesign program supported by generative models.

Lessons for Scaling Generative AI Use Cases

The first lesson was to select a workflow with a deadline, stable ownership, accessible evidence, and measurable baseline. IND preparation met those conditions and created reusable capabilities. Beginning with an enterprise-wide assistant would have spread attention across too many evidence standards and failure modes.

The second lesson was to preserve the boundaries between functions. Regulatory affairs, clinical development, pharmacovigilance, and CMC reused infrastructure but maintained different acceptance criteria and review authority. A safety case cannot inherit the control model of a literature-summary tool, and a deviation hypothesis cannot become a lot-disposition decision merely because it is well phrased.

The third lesson was to measure rejected outputs and reviewer burden, not only accepted drafts. Meridian learned as much from the 53 discovery hypotheses that did not progress as from the two that influenced experiments. Override patterns revealed where model confidence and reviewer effort were misaligned. Generative AI Use Cases improved when failure data became part of routine monitoring.

Finally, the company treated traceability as a usability feature. Scientists trusted summaries more when they could inspect the exact study, table, batch, or case behind a claim. Pharmaceutical AI Solutions gained adoption because evidence review was easier, not because users were asked to trust increasingly humanlike language.

Conclusion

Meridian's case shows a credible route from experimentation to scaled value: anchor each application to a constrained pharmaceutical decision, curate the necessary evidence, preserve provenance, validate against authentic tasks, and keep qualified experts accountable. Across IND authoring, translational research, protocol design, safety surveillance, and technology transfer, the strongest results came from faster synthesis and earlier risk identification rather than autonomous decisions. Organizations evaluating Pharmaceutical AI Solutions should demand this level of specificity from their roadmaps and metrics. Generative AI Use Cases can materially improve development productivity, but only when models are embedded in the scientific, GxP, and quality disciplines that make pharmaceutical evidence defensible.